Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119867 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL4575275 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29402209 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29383097 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119365 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29447672 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL17359219 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30792899 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL27028706 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119560 | 0.96 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4339204-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4844/4885SMN1; SMN2 4182/4885RAB9A 130/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-20240239842-A1 | BINDING MOLECULE EXHIBITING SELECTIVE BINDING FOR RAS(G12D) MUTANT | KRAS, G3BP1, G3BP2 | ALDH1A1 3749/4885SMN1; SMN2 3436/4885RAB9A 75/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | ALDH1A1 4861/4885SMN1; SMN2 4745/4885RAB9A 98/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | ALDH1A1 4331/4885SMN1; SMN2 4564/4885RAB9A 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.